EUVIMEDSkopri EUVIMED
MetaanalyseSystematische ÜbersichtOpen access · CC BY-NC-ND 4.0

Progestogens in women with threatened miscarriage or recurrent miscarriage: A meta‐analysis

Yunli Zhao iD, Rohan D'Souza, Ya Gao, Qiukui Hao, Lucas Kallas-Silva, Jeremy P Steen, Gordon Guyatt

Acta Obstetricia et Gynecologica Scandinavica · 2024-09 · 103 (9) · 1689-1701

DOI: 10.1111/aogs.14829 ↗

At a glance

Metaanalyse in Acta Obstetricia et Gynecologica Scandinavica, published online on 2024-03-13. Written by Yunli Zhao and 6 co-authors. Institution: Department of Geriatric Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. Major MEDLINE topics: Abortion, Habitual, Progestins, Abortion, Threatened. Cited 20 times so far (Crossref); 60 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Introduction

Clinical practice guidelines provide inconsistent recommendations regarding progestogen supplementation for threatened and recurrent miscarriage. We conducted a systematic review and meta‐analysis to assess the effectiveness and safety of progestogens for these patients. Material and methods We searched Medline, Embase, and Cochrane Central Registry of Controlled Trials up to October 6, 2023 for randomized control trials (RCTs) comparing progestogen supplementation to placebo or no treatment for pregnant women with threatened or recurrent miscarriage. We assessed the risk of bias using a modified version of the Cochrane risk‐of‐bias tool and the certainty of evidence using the GRADE approach.

Results

Of 15 RCTs (6616 pregnancies) reporting on threatened or recurrent miscarriage, 12 (5610 pregnancies) reported on threatened miscarriage with or without a prior history of miscarriage. Results indicated that progesterone probably increases live births (relative risk (RR) 1.04, 95% confidence interval (CI) 0.99–1.10, absolute increase 3.1%, moderate certainty). Of these RCTs, three (1973 pregnancies) reporting on threatened miscarriage with a prior history of miscarriage indicated that progesterone possibly increases live births (RR 1.06, 95% CI: 0.97–1.16, absolute increase 4.4%; low certainty), while four (2540 pregnancies) reporting on threatened miscarriage and no prior miscarriage left the effect very uncertain (RR 1.02, 95% CI: 0.96–1.10, absolute increase 1.7%; very low certainty). Three trials reporting on 1006 patients with a history of two or more prior miscarriages indicated progesterone probably increases live births (RR 1.08, 95% CI: 0.98–1.19, absolute increase 5.7%, moderate certainty). Six RCTs that reported on 2979 patients with at least one prior miscarriage indicated that progesterone probably increases live births (RR 1.07, 95% CI: 1.01–1.13, absolute increase 5.0%; moderate certainty). Progesterone probably has little or no effect on congenital anomalies (RR 1.06, 95% CI: 0.76–1.48, absolute increase 0.1%; moderate certainty), and other serious adverse pregnancy events (RR 1.07, 95% CI: 0.83–1.40, absolute increase 0.2%, moderate certainty).

Conclusions

In women at increased risk of pregnancy loss, progestogens probably increase live births without increasing adverse maternal and neonatal events. It remains possible that the benefit is restricted to those with prior miscarriages.

Subjects

MeSH terms (MEDLINE)

Abortion, HabitualProgestinsAbortion, ThreatenedHumansFemalePregnancyRandomized Controlled Trials as TopicProgesterone

Author keywords

live birthmeta‐analysisprogestogensrecurrent miscarriagethreatened miscarriage

Substances

ProgestinsProgesterone

Authors and institutions

  • Department of Geriatric Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • Chongqing Municipality Clinical Research Center for Geriatrics, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • The Center of Gerontology and Geriatrics (National Clinical Research Center for Geriatrics), West China Hospital, Sichuan University, Chengdu, China.
  • Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.
  • Department of Obstetrics and Gynecology, McMaster University, Hamilton, Ontario, Canada.
  • Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China.

ORCID profiles: Yunli Zhao

Cite

APA

Zhao, Y., D'Souza, R., Gao, Y., Hao, Q., Kallas-Silva, L., Steen, J. P., & Guyatt, G. (2024). Progestogens in women with threatened miscarriage or recurrent miscarriage: A meta‐analysis. Acta Obstetricia et Gynecologica Scandinavica, 103(9), 1689-1701. https://doi.org/10.1111/aogs.14829

Vancouver

Zhao Y, D'Souza R, Gao Y, Hao Q, Kallas-Silva L, Steen JP, et al. Progestogens in women with threatened miscarriage or recurrent miscarriage: A meta‐analysis. Acta Obstetricia et Gynecologica Scandinavica. 2024;103(9):1689-1701. doi:10.1111/aogs.14829

BibTeX
@article{Zhao2024,
  author = {Zhao, Yunli and D'Souza, Rohan and Gao, Ya and Hao, Qiukui and Kallas-Silva, Lucas and Steen, Jeremy P and Guyatt, Gordon},
  title = {Progestogens in women with threatened miscarriage or recurrent miscarriage: A meta‐analysis},
  journal = {Acta Obstetricia et Gynecologica Scandinavica},
  year = {2024},
  volume = {103},
  number = {9},
  pages = {1689--1701},
  doi = {10.1111/aogs.14829}
}
Start for free →